Method of inhibiting harmful microorganisms and barrier-forming composition therefor
Inventors
Sokol, Brian Vincent • Ghannoum, Afif Mahmoud
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10398645-B2
Publication Date
2019-09-03
Expiration Date
Abstract
A method for blocking, neutralizing, or killing microorganisms that cause infectious disease in a mammal prior to or during the mammal encountering a contaminated environment or item includes: identifying a contaminated environment or item, wherein the contaminated environment or item is known or expected to be contaminated with harmful viral, fungal, or bacterial microorganisms; and administering a therapeutically effective amount of a barrier-forming composition to a mucosa of the mammal prior to or during the mammal encountering the contaminated environment or item. The barrier-forming composition provides a barrier on the mucosa that inhibits the microorganisms from contacting the mucosa. Other related methods are also included.
Core Innovation
The invention provides barrier-forming antimicrobial compositions and methods for preventing or reducing the risk of infectious disease in a host. A therapeutically effective amount of the composition is administered to a mucosa of the host by spraying or mouthwash delivery, with the composition forming a barrier on the mucosa that is active to trap, and kill or neutralize microorganisms.
The barrier-forming composition is characterized by specified amounts of a carbohydrate gum (C), a humectant (H), and an antimicrobial agent (A), wherein all percentages are by weight of the total composition. The antimicrobial agent is a quaternary ammonium antimicrobial agent, including cetylpyridinium chloride or a pharmaceutically acceptable salt thereof in dependent claims.
The methods address infectious disease caused by microorganisms that cause one or more upper respiratory infections, one or more cold viruses, or influenza viruses, and also include microorganisms selected from a defined group including Candida, pneumonia, MRSA, Streptococcus, Porphyromonas gingivalis, Acinetobacter baumannii, Aggregatibacter actinomycetemcomitans, Fusobacterium nucleatum, Yersinia enterocolitica, Epstein-Barr virus, cold viruses, and influenza viruses. In one independent claim, the composition includes specific weight-percent ranges and a pH of about 4 to about 7, and at least one claim includes a proviso that the method is not administered for prevention or treatment of dental disease.
Claims Coverage
The partial content includes three independent claims, each centered on mucosal delivery of a barrier-forming antimicrobial composition and barrier activity to trap and kill or neutralize microorganisms. Across the independent claims, inventive features cover prevention or inhibition of infectious disease for specified pathogens, reduction of infectious-disease risk after barrier application, and composition formulation constraints including carbohydrate gum, humectant, quaternary ammonium antimicrobial agent, and pH ranges.
Spraying or mouthwash delivery of a barrier-forming antimicrobial composition to mucosa for prevention
Administering by spraying or mouthwash delivery, a therapeutically effective amount of a composition to a mucosa of the host, wherein the composition forms a barrier on the mucosa that is active to trap, and kill or neutralize microorganisms.
Carbohydrate gum, humectant, and quaternary ammonium antimicrobial formulation
The composition comprising about 0.01%≤C≤about 0.4%, about 7%≤H≤about 65%, and 0.050%<A, wherein C is a carbohydrate gum, H is a humectant, and A is an antimicrobial agent that is a quaternary ammonium compound.
Prevention targeting upper respiratory infections, cold viruses, and influenza viruses
The infectious disease is caused by microorganisms that cause one or more upper respiratory infections, one or more cold viruses, or influenza viruses.
Risk reduction from microorganisms encountered subsequent to barrier application
Administering by spraying or mouthwash delivery, a therapeutically effective amount of the barrier-forming composition to a mucosa of the host for at least about two consecutive days and at least three times daily, wherein the infectious disease is caused by microorganisms selected from the group consisting of Candida, pneumonia, MRSA, Streptococcus, Porphyromonas gingivalis, Acinetobacter baumannii, Aggregatibacter actinomycetemcomitans, Fusobacterium nucleatum, Yersinia enterocolitica, microorganisms that cause upper respiratory infections, Epstein-Barr virus, cold viruses, and influenza viruses, and wherein the composition forms a barrier on the mucosa that is active to trap, and kill or neutralize microorganisms, with the proviso that the method is not administered for prevention or treatment of dental disease.
Inhibiting contraction using barrier-forming composition with pH control
Administering a therapeutically effective amount of a composition by spraying or mouthwash delivery, to a mucosa of the host, wherein the composition comprises about 0.01%≤C≤about 0.4%, about 7%≤H≤about 65%, and 0.050%<A<1% (by weight of the total composition), wherein C is a carbohydrate gum, H is a humectant, and A is an antimicrobial agent; the antimicrobial is a quaternary ammonium compound; and the pH of the composition is about 4 to about 7.
Across the independent claims, coverage focuses on mucosal administration of a barrier-forming antimicrobial composition containing a carbohydrate gum, humectant, and quaternary ammonium antimicrobial agent, with barrier activity to trap and kill or neutralize microorganisms. Target scope includes upper respiratory infections, cold viruses, influenza viruses, and a broader listed set of microorganisms, with one claim adding multi-day, at-least-three-times-daily administration and another adding composition pH limitations.
Stated Advantages
Forms a barrier on the mucosa that is active to trap, and kill or neutralize microorganisms.
Prevents infectious disease in a host.
Reduces risk of infectious disease in a host from microorganisms encountered subsequent to application of the barrier-forming composition.
Inhibits contraction of infectious disease in a host.
Documented Applications
Prevention of infectious disease in a host, including infectious diseases caused by microorganisms that cause one or more upper respiratory infections, one or more cold viruses, or influenza viruses.
Reducing risk of infectious disease in a host from microorganisms encountered subsequent to application of a barrier-forming composition.
Inhibiting the contraction of infectious disease in a host.
A method that is not administered for prevention or treatment of dental disease.
Interested in licensing this patent?